HealthcareServices

Mucopolysaccharidosis Treatment Market Insights Report: Opportunities and Drivers 2030

February 26, 2026March 4, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the mucopolysaccharidosis treatment market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Mucopolysaccharidosis Treatment Market by the end of 2030?

The mucopolysaccharidosis treatment market size has seen robust growth over recent years. It is anticipated to expand from $2.58 billion in 2025 to $2.78 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.7%. This historical progression can be linked to conditions including limited awareness of MPS disorders, high treatment costs, the gradual adoption of enzyme therapy, restricted availability of clinical trials, and a reliance on international drug supplies.

The mucopolysaccharidosis treatment market is anticipated to show robust expansion over the next few years. It is forecast to grow to $3.79 billion by 2030, achieving a compound annual growth rate (CAGR) of 8.0%. This projected growth is driven by factors such as the expansion of gene therapy research, increasing investments in healthcare, improved rare disease screening programs, broader reimbursement coverage, and the advancement of precision medicine platforms. Noteworthy trends during the forecast period include innovations in enzyme replacement therapy, the rising adoption of stem cell transplantation, the increased development of gene therapy approaches, a growing emphasis on early diagnosis and newborn screening, and the expansion of specialized treatment centers.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp

What Drivers Are Shaping Future Opportunities In The Mucopolysaccharidosis Treatment Market?

The rising occurrence of various forms of mucopolysaccharidosis is anticipated to drive the expansion of the mucopolysaccharidosis treatment market in the coming years. Mucopolysaccharide is a complex carbohydrate that accumulates within bodily tissues because affected individuals lack the specific enzyme required for its digestion. Mucopolysaccharidosis (MPS) therapy offers various therapeutic strategies to help prevent disease progression by diminishing glycosaminoglycan (GAG) formation in the body, managing symptoms, and preventing complications. For instance, in July 2024, the Orphanet Journal of Rare Diseases, a France-based peer-reviewed open-access medical journal, estimated the incidence of mucopolysaccharidosis IVa (MPS IVa) at around 1 in 201,000 live births, though this figure is believed to differ considerably among various populations. Likewise, the birth prevalence of Mucopolysaccharidosis VI (MPS VI) is projected to range between 1 in 43,261 and 1 in 1,505,160, contingent on the population. Therefore, the growing prevalence of diverse forms of mucopolysaccharidosis will propel the mucopolysaccharidosis treatment market.

Which Segments Are Gaining Traction In The Mucopolysaccharidosis Treatment Market?

The mucopolysaccharidosis treatment market covered in this report is segmented –

1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy

2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases

3) By Route Of Administration: Intravenous, Intracerebroventricular

4) By End-User: Hospitals, Specialty Clinics, Other End-Users

Subsegments:

1) By Enzyme Replacement Therapy: Idursulfase (Elaprase), Laronidase (Aldurazyme), Velaglucerase Alfa (Vpriv), Galsulfase (Naglazyme)

2) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT), Umbilical Cord Blood Transplantation, Gene Therapy Approaches

Which Trends Are Expected To Influence The Mucopolysaccharidosis Treatment Market In The Upcoming Years?

Leading firms within the MPS II treatment market are concentrating on creating novel therapies, specifically AAV gene therapies, with the aim of targeting the core genetic causes of the condition and achieving lasting neurological improvement. Such AAV gene therapies represent precise genetic approaches, utilizing adeno-associated viral vectors to introduce operational genes into central nervous system cells, thus facilitating the sustained generation of absent or insufficient proteins. For example, during August 2025, REGENXBIO Inc., a biotechnology firm located in the US, announced that the United States Food and Drug Administration had prolonged its review period for RGX-121. This extension resulted from the submission of long-term clinical trial data from all key study participants, demonstrating continued consistency with prior biomarker and neurodevelopmental findings. Favorable pre-license inspections and no identified safety issues suggest sustained regulatory progress, bolstering the therapy’s promise as potentially the inaugural single-dose treatment designed to address the neurological symptoms of MPS II.

Who Are The Prominent Global Companies Shaping The Mucopolysaccharidosis Treatment Market Landscape?

Major companies operating in the mucopolysaccharidosis treatment market are BioMarin Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Abeona Therapeutics Inc., Immusoft Corporation, Neurogene Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Denali Therapeutics Inc., Passage Bio Inc., Homology Medicines Inc., AVROBIO Inc., Rocket Pharmaceuticals Inc., Taysha Gene Therapies Inc., Freeline Therapeutics Holdings plc, 4D Molecular Therapeutics Inc., Sio Gene Therapies Inc., SpliceBio S.L., LogicBio Therapeutics Inc., Orchard Therapeutics plc, Asklepios BioPharmaceutical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/mucopolysaccharidosis-treatment-global-market-report

How Does The Mucopolysaccharidosis Treatment Market Perform Across Major Global Regions?

North America was the largest region in the mucopolysaccharidosis treatment market in 2025. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Mucopolysaccharidosis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11942&type=smp

Browse Through More Reports Similar to the Global Mucopolysaccharidosis Treatment Market 2026, By The Business Research Company

Anticoccidial Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticoccidial-drugs-global-market-report

Mucolipidosis Ii Market Report 2026

https://www.thebusinessresearchcompany.com/report/mucolipidosis-ii-global-market-report

Lysosomal Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/lysosomal-disease-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795